HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Borneman, J. P. Articles by Field, R. I. Search for Related Content PubMed PubMed Citation Articles by Borneman, J. P. Articles by Field, R. I.

JOHN P. BORNEMAN is Board Member, Homeopathic Pharmacopoeia Convention of the United States, Southeastern, PA, and Chairman, Standard Homeopathic Company, Bryn Mawr, PA. ROBERT I. FIELD is Director, Health Policy Program, University of the Sciences in Philadelphia, Philadelphia, PA.

Address correspondence to Mr. Borneman at Box 87, Bryn Mawr, PA 19010 (jborneman{at}hylands.com).

Purpose. The regulation of homeopathic drug products is discussed. Summary. Homeopathy is a system of medicine based on the observation that high doses of pharmacologically active substances cause symptoms when administered to healthy individuals. These same substances, when prepared in very dilute form, may relieve similar symptoms in conditions resulting from different etiologies. Unlike dietary supplements, homeopathic drugs are subject to the Food, Drug, and Cosmetic Act and regulations issued by FDA. Instead of the new-drug-approval process, premarket approval for homeopathic drugs is by way of monograph approval by the Homeopathic Pharmacopoeia Convention of the United States (HPCUS). Monographs are published in the Homeopathic Pharmacopoeia of the United States (HPUS). The criteria for inclusion in the HPUS require that a homeopathic drug product be determined by HPCUS to be safe and effective and to be prepared according to the specifications of the HPUS general pharmacy section. The long history and established nature of homeopathic drug regulation may provide a model for the regulation of dietary supplements. Conclusion. Homeopathic drugs in the United States are subject to well-defined regulatory processes that more closely resemble those that apply to allopathic medications than to dietary supplements. Index terms: Alternative medicine; Food and Drug Administration (U.S.); Food, Drug, and Cosmetic Act; Homeopathic Pharmacopoeia; Homeopathy; Regulations; Toxicity